2250. Metformin for Preventing Diabetes Mellitus in HIV-infected Patients with Prediabetes: A Randomized Controlled Trial
Session: Poster Abstract Session: HIV: Metabolic, Cardiovascular, and Renal Complications
Saturday, October 6, 2018
Room: S Poster Hall
Background: Both HIV and diabetes mellitus (DM) increase the risk for cardiovascular diseases. Prediabetes (PreDM), a condition preceding DM, is commonly observed in HIV-infected patients receiving antiretroviral therapy (ART). Both metformin and lifestyle interventions have been shown to reduce risk of progression to DM in non-HIV infected population. This study aimed to evaluate the efficacy of metformin for preventing DM in HIV-infected patients.

Methods: An open-label randomized controlled clinical trial was conducted in HIV-infected patients with PreDM. Patients were randomized into 2 groups: metformin group (received metformin) and control group (not received metformin). Patients in both groups were counseled regarding diet control and lifestyle modification and followed for 6 months. The primary endpoint was the development of DM. Fasting plasma glucose (FPG), 2-hr 75-gm oral glucose tolerance test, HbA1c, computer-based homeostatic model assessment index of beta-cell function (HOMA%B) and insulin resistance (HOMA-IR) were analyzed.

Results: 74 patients were enrolled, 37 in each group. Mean age was 49.6 years and 68.9% were males. At baseline, mean CD4 cell count was 570 cells/mm3 and mean body mass index (BMI) was 24.6 kg/M2. Baseline characteristics including age, sex, BMI, waist-hip (W/H) ratio, duration of ART, ART regimen, CD4 cell count and HIV RNA were similar between 2 groups (p >0.05). Mean FPG, 2hPG, HbA1c, HOMA%B and HOMA-IR at baseline were also similar between 2 groups (p >0.05). At 6 months, 1 patient in metformin group and 2 in control group developed DM [risk reduction 2.70%; 95% CI, −9.09% to +15.20%]. Mean HbA1c significantly decreased from baseline only in metformin group. HOMA-IR at 6 months was significantly lower in metformin group (1.086 vs 1.478, p=0.042). However, BMI, W/H ratio, FPG, 2hPG, HbA1c, and HOMA%B at 6 months were not significantly different between 2 groups (p >0.05). No patient had adverse effects that led to discontinuation of metformin. No cardiovascular event was observed in study period.

Conclusion: Metformin appears to improve insulin resistance and prevent progression to DM in HIV-infected patients with PreDM. Further study with longer study period is needed to evaluate long-term benefit of metformin.

Sitta Jiriyasin, M.D.1, Hataikarn Nimitphong, M.D.1 and Somnuek Sungkanuparph, M.D.2, (1)Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, (2)Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

Disclosures:

S. Jiriyasin, None

H. Nimitphong, None

S. Sungkanuparph, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.